Skip to main content
OpenTrials
Completed

NCT Number: NCT00163059

The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

To determine if the NMDA antagonist, CP-101,606, is effective for depression

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Depressive Disorder, Major Depressive Disorder Mental Disorders Mood Disorders

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Pfizer Investigational Site

Wichita, Kansas, 67214-2878, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Primary DSM-IV diagnosis of MDD

Exclusion criteria

  • Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Treatment and study plan

NMDA Antagonist, CP-101,606 (traxoprodil)

Drug

Primary outcomes

  1. MADRS

Secondary outcomes

  1. HAM-D

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Randomized, Double-Blinded, Placebo-Controlled Trial To Assess The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With Treatment Refractory Major Depressive Disorder

Important dates

Study start
2004
Study completion
2005
First posted
Sep 13, 2005
Registry last updated
Sep 22, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.